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Background & aims: Systemic iron status affects multiple health outcomes, however its net effect on life
expectancy is not known. We conducted a two-sample Mendelian randomization (MR) study to inves-
tigate the association of genetically proxied iron status with life expectancy.
Methods: Using genetic data from 48,972 individuals, we identified three genetic variants as instru-
mental variables for systemic iron status. We obtained genetic associations of these variants with
parental lifespan (n ¼ 1,012,240) and individual survival to the 90th vs. 60th percentile age (11,262 cases
and 25,483 controls). We used the inverse-variance weighted method to estimate the effect of a 1-
standard deviation (SD) increase in genetically predicted serum iron on each of the life expectancy
outcomes.
Results: We found a detrimental effect of genetically proxied higher iron status on life expectancy. A 1-
SD increase in genetically predicted serum iron corresponded to 0.70 (95% confidence interval
[CI] 1.17, 0.24; P ¼ 3.00  103) fewer years of parental lifespan and had odds ratio 0.81 (95% CI 0.70,
0.93; P ¼ 4.44  103) for survival to the 90th vs. 60th percentile age. We did not find evidence to suggest
that these results were biased by pleiotropic effects of the genetic variants.
Conclusions: Higher systemic iron status may reduce life expectancy. The clinical implications of this
finding warrant further investigation, particularly in the context of iron supplementation in individuals
with normal iron status.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Iron is vital to human health. Systemic iron status can be
assessed using biomarkers such as serum iron, ferritin, transferrin
(inversely related to iron status) and transferrin saturation. Levels
of these biomarkers vary considerably between individuals, and
can be altered through clinical intervention. Small changes in iron
status have been suggested to have protective and detrimental ef-
fects on different disease processes [1e4]. However, the net effect
of varying systemic iron levels on life expectancy remains unclear.
This is of clinical relevance, as up to 19% of the US population takes
an iron supplement [5].
While observational studies have associated higher iron status
with reduced life expectancy, such a study design is limited in its
ability to draw causal inference due to the possibility of con-
founding and reverse causation [6]. For example, dietary patternsShattuck Street, Boston, MA
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Genetically predicted iron smay influence both iron status and longevity, thereby inducing a
spurious relationship between these two entities. Furthermore,
biomarkers of iron status are influenced by acute and chronic
inflammation, and may therefore be an indicator rather than a
cause of disease.
The Mendelian randomization (MR) approach can overcome
these limitations by using randomly allocated genetic variants as
instrumental variables for studying the causal effects of modifying
systemic iron status [2]. As germline genetic variation cannot be
modified by the environment, this method is more robust to con-
founding and reverse causality. The aim of this study was to use MR
to investigate the effect of genetically predicted systemic iron sta-
tus on life expectancy.2. Methods
2.1. Genetic instruments for iron status
As instrumental variables for systemic iron status, we selected
single-nucleotide polymorphisms (SNPs) that had genome-wideunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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status (serum iron, transferrin, transferrin saturation and ferritin)
in a pattern with concordant effects on overall iron status [1,2,4,7].
The use of such a stringent significance threshold ensures that the
SNPsmay bemodelled as strong instrumental variables for MR, and
the association of the variants with all four biomarkers of iron
status improves their validity as instruments for systemic iron
status [1,2,4]. This approach identified three independent missense
variants in genes implicated in iron homeostasis (rs1800562 e HFE,
rs1799945 e HFE, rs855791 e TMPRSS6) [1,2,4,7]. Putative biolog-
ical roles for these genes in iron homeostasis have been previously
described [2]. Briefly, in the setting of excessive iron stores, HFE
may inhibit iron absorption by inducing hepcidin production. In the
setting of iron depletion, TMPRSS6 may stimulate iron absorption
by inhibiting hepcidin production.
2.2. Life expectancy outcomes
Large-scale genetic association studies on individual lifespan are
not available. However, parental lifespan is a readily available
phenotype that can be used as an outcome in a genetic association
study because parents share half of their genetic code with their
offspring [8]. As the primary outcome of the present analysis, we
obtained genetic association estimates for the variants selected as
iron status instruments with parental survival from ameta-analysis
of the UK Biobank and LifeGen consortium (n ¼ 1,012,240) [8].
These studies used a Cox proportional hazards model to estimate
offspring SNP effects on parental survival. Effect sizes from this
approach, using offspring genetic data, are half of the actual variant
effect size in the parent [8], and were therefore doubled to reflect
the expected genetic effects in parents. This approach effectively
imputes the parental genotype data. The genetic effects from this
study may be multiplied by ten to estimate the absolute change in
lifespan years [8]. Data on the SNP-iron and SNP-longevity associ-
ations were harmonized by orienting effects to the same allele
(Supplementary Table 1).
As a secondary outcome, we obtained genetic associations of
these instruments with odds of individual (i.e. non-parental) sur-
vival to a sex and birth cohort-specific 90th percentile age vs. 60th
percentile age (11,262 cases, 25,483 controls) [9]. As example sur-
vival percentiles, the 60th and 90th percentile ages in the 1920 US
birth cohort correspond to 75 and 89 years for men and 83 and 102
years for women [9]. The genetic effects from this study are pro-
vided as log-odds of survival to the 90th vs. 60th percentile age.
All included genetic association studies were conducted in Eu-
ropean populations and adjusted for principal components of
ancestry, thereby minimizing confounding by population stratifi-
cation. All studies received relevant ethical approval and partici-
pant consent and their data are publicly available, as detailed in the
supporting citations [7e9].
2.3. Statistical analysis
For the three genetic variants, we used the ratio method to es-
timate the instrumental effect of higher iron status on life expec-
tancy. This method divides the SNP-outcome effects by the SNP-
exposure effects and uses first-order weights to obtain the stan-
dard error of the causal effect [10]. To pool the effects across all
three variants, we implemented the random-effects inverse-vari-
ance weighted method [10]. This method regresses the SNP-
outcome association on the SNP-exposure association and
weights the effects by the inverse of the standard error of the SNP-
outcome associations, with the intercept constrained at the origin
[10]. We provide estimates that are scaled to a 1-standard deviation
(SD) increase in iron status biomarker.Please cite this article as: Daghlas I, Gill D, Genetically predicted iron s
j.clnu.2020.06.025MR estimates may be biased by horizontal pleiotropy if the
genetic variants proxying iron status influence longevity through a
pathway independent of iron status. To test the null hypothesis of
no pleiotropy, we calculated Cochran's Q for heterogeneity and
used the P-value to assess the strength of evidence for pleiotropy
[10]. We also performed analyses using theMR-Egger andweighted
median methods, which can be robust to inclusion of pleiotropic
variants [10]. As these analyses may be unreliable when only using
three variants, we broadened the instrument selection criteria to
include variants meeting the following criteria: i) associated with
any 1 iron status biomarker at genome-wide significance and ii)
associated with the other biomarkers in a pattern consistent with
an effect on overall iron status, irrespective of the significance of
association [4]. This approach identified three additional variants
for use as genetic instruments for systemic iron status
(Supplementary Table 2).
All analyses were implemented using the TwoSampleMR pack-
age of R [10].
3. Results
Genetically predicted higher iron status across all biomarkers
was associated with reduced life expectancy (Figs. 1 and 2). The
association of a 1-SD increase in genetically predicted iron status
biomarker with lifespan years was 0.70 for iron (95% confidence
interval [CI]1.17,0.24; P¼ 3.00 103),1.64 for ferritin (95% CI
e2.31, 0.96; P ¼ 2.01  106), 0.54 for transferrin saturation
(95% CI0.76,0.32; P¼ 1.69 106), and 0.78 for transferrin (95%
CI 0.41, 1.14; P¼ 2.92 105). The odds ratio for survival to the 90th
vs. 60th percentile age was 0.81 for iron (95% CI 0.70, 0.94;
P ¼ 4.44  103), 0.63 for ferritin (95% CI 0.44, 0.90;
P ¼ 1.05  102), 0.86 for transferrin saturation (95% CI 0.77, 0.96;
P ¼ 7.78  103), and 1.21 for transferrin (95% CI 0.94, 1.56;
P ¼ 1.42  101). Individual variant MR estimates were all consis-
tent with a deleterious effect of higher genetically predicted iron
status on lifespan and longevity with no statistical evidence of
heterogeneity (all P  0.05; Figs. 1 and 2). Further sensitivity ana-
lyses using the MR-Egger and weighted median methods all pro-
vided consistent evidence with confidence intervals overlapping
those obtained from the inverse-variance weighted method
(Supplementary Tables 3 and 4). The MR-Egger intercept test did
not provide evidence for unbalanced pleiotropy (all P  0.18).
4. Discussion
We found that higher genetically predicted iron status was
associated with reduced life expectancy. This effect was consistent
across all four biomarkers of systemic iron status, and across the
outcomes of lifespan and longevity. The lack of heterogeneity
across the genetic instruments and the consistency of evidence
across statistical sensitivity analyses suggests that our findings are
unlikely to be biased by pleiotropic effects of the variant used to
proxy systemic iron status. While the association of genetically
predicted transferrin levels with longevity in the secondary anal-
ysis was the only result where the confidence intervals overlapped
the null, this is likely attributable to inadequate statistical power,
and the direction of the point estimate was concordant with the
other results.
Taken together, these findings suggest that associations be-
tween higher iron status and increased mortality risk reported in
prior observational studies may reflect causal relationships [6]. Our
findings suggest that, on average for the populations considered,
any protective effects of an increase in iron status for certain out-
comes are outweighed by deleterious effects on risk of other dis-
eases. Prior MR studies have suggested that higher iron statustatus and life expectancy, Clinical Nutrition, https://doi.org/10.1016/
Fig. 1. Forest plot of Mendelian randomization estimates for the association between genetically predicted iron status biomarkers and lifespan (n ¼ 1,012,240). Point es-
timates are expressed as change in lifespan years per standard deviation increase in genetically predicted iron status biomarker. ‘Combined estimate’ reports the effect estimated by
the inverse-variance weighted method. CI: confidence interval; het: heterogeneity; sat: saturation.
Fig. 2. Forest plot of Mendelian randomization estimates for the association between genetically predicted iron status biomarkers and survival to the 90th vs. 60th
percentile age (11,262 cases/25,483 controls). Point estimates are expressed as the odds ratio (OR) for survival to the 90th vs. 60th percentile age per standard deviation increase in
genetically predicted iron status biomarker. ‘Combined estimate’ reports the effect estimated by the inverse-variance weighted method. CI: confidence interval; het: heterogeneity;
sat: saturation.
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terolemia [2]. By contrast, MR studies have found deleterious ef-
fects of higher iron status on risk of skin infection [2], rheumatoid
arthritis [3], and cardioembolic stroke [4]. Lifespan and longevity
may be considered in relation to all these effects over the life
course, thereby offering a holistic perspective on the consequence
of intervening on a risk factor.
Our findings should be interpreted in context. Despite our ef-
forts, the MR estimates may still be biased by pleiotropic effects ofPlease cite this article as: Daghlas I, Gill D, Genetically predicted iron s
j.clnu.2020.06.025the genetic variants on life expectancy through pathways inde-
pendent of iron status. Prior work has shown that the iron status
raising allele at rs1800562 in HFE lowers low-density lipoprotein
cholesterol levels, while the iron status raising allele at rs1799945
in HFE raises systolic and diastolic blood pressure [1]. However, we
found consistent estimates in sensitivity analyses and little evi-
dence of heterogeneity, suggesting that any bias attributable to
these pleiotropic effects is unlikely to be large. Furthermore, this
MR approach only considers the linear associations of smalltatus and life expectancy, Clinical Nutrition, https://doi.org/10.1016/
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mean, and cannot be extrapolated to infer the effect of changes in
iron status outside of this normal range. As genetic variation causes
lifelong changes in iron status, these results cannot be extrapolated
to predict the effect of a discrete clinical intervention that modifies
iron status. This analysis was conducted using data from European-
ancestry population-based studies, and may not generalize to other
populations. Finally, this study design does not inform on the bio-
logical mechanisms by which systemic iron status influences life
expectancy.
In conclusion, our genetic evidence suggests that an increase
in systemic iron status around the population mean may reduce
life expectancy. While randomized-controlled trials are required
to provide definitive evidence of clinical effect, and further
research is required to validate the clinical implications of our
findings, caution may be prudent when supplementing iron
without a clear clinical indication, such as in individuals with
normal iron status.Role of the funding sources
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